29 Mar 2017 13:57
29 March 2017
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Issue of Equity
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that an application has been made by the Company to the London Stock Exchange and the Irish Stock Exchange for 45,000 new ordinary shares of nominal value of £0.001 each in the Company ("Ordinary Shares") to be admitted to trading on the AIM market of the London Stock Exchange and the ESM market of the Irish Stock Exchange. The new Ordinary Shares will rank in pari passu with the existing Ordinary Shares in issue.
The new Ordinary Shares are being issued in consideration of services rendered to the Company during 2016. Dealings are expected to commence in these new Ordinary Shares on at 8:00 a.m. on 4 April 2017.
Following admission of these new Ordinary Shares, Venn's issued share capital will consist of 60,284,263 Ordinary Shares.
Enquiries:
Venn Life Sciences Holdings Plc | ||
Allan Wood, Non-Executive Chairman | ||
Tony Richardson, Chief Executive Officer | Tel: +353 1 5499341 | |
Davy (Nominated Adviser and Broker) | ||
Fergal Meegan / Matthew de Vere White (Corporate Finance) | Tel: +353 1 679 6363 | |
Orla Bolger (Corporate Broking) | ||
Hybridan LLP (Co-Broker) | Tel: +44 (0)20 3764 2341 | |
Claire Louise Noyce | ||
Walbrook PR Ltd | Tel: +44(0)20 7933 8787 | |